<VariationArchive VariationID="2836128" VariationName="NM_025243.4(SLC19A3):c.1212dup (p.Val406fs)" VariationType="Duplication" Accession="VCV002836128" Version="1" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-03-05" DateCreated="2024-02-20" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="2992115" VariationID="2836128">
      <GeneList>
        <Gene Symbol="SLC19A3" FullName="solute carrier family 19 member 3" GeneID="80704" HGNC_ID="HGNC:16266" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>2q36.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="227683763" stop="227718028" display_start="227683763" display_stop="227718028" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="228549925" stop="228582744" display_start="228549925" display_stop="228582744" Strand="-" />
          </Location>
          <OMIM>606152</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_025243.4(SLC19A3):c.1212dup (p.Val406fs)</Name>
      <CanonicalSPDI>NC_000002.12:227688267:GG:GGG</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>2q36.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="227688267" stop="227688268" display_start="227688267" display_stop="227688268" variantLength="1" positionVCF="227688267" referenceAlleleVCF="A" alternateAlleleVCF="AG" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="228552983" stop="228552984" display_start="228552983" display_stop="228552984" variantLength="1" positionVCF="228552983" referenceAlleleVCF="A" alternateAlleleVCF="AG" />
      </Location>
      <ProteinChange>V406fs</ProteinChange>
      <ProteinChange>V402fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.11" sequenceAccession="NC_000002" sequenceVersion="11" change="g.228552985dup" Assembly="GRCh37">
            <Expression>NC_000002.11:g.228552985dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.12" sequenceAccession="NC_000002" sequenceVersion="12" change="g.227688269dup" Assembly="GRCh38">
            <Expression>NC_000002.12:g.227688269dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_016359.1" sequenceAccession="NG_016359" sequenceVersion="1" change="g.34762dup">
            <Expression>NG_016359.1:g.34762dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001371411.1" sequenceAccession="NM_001371411" sequenceVersion="1" change="c.1212dup">
            <Expression>NM_001371411.1:c.1212dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001358340.1" sequenceAccession="NP_001358340" sequenceVersion="1" change="p.Val406fs">
            <Expression>NP_001358340.1:p.Val406fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001371412.1" sequenceAccession="NM_001371412" sequenceVersion="1" change="c.1212dup">
            <Expression>NM_001371412.1:c.1212dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001358341.1" sequenceAccession="NP_001358341" sequenceVersion="1" change="p.Val406fs">
            <Expression>NP_001358341.1:p.Val406fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001371413.1" sequenceAccession="NM_001371413" sequenceVersion="1" change="c.1200dup">
            <Expression>NM_001371413.1:c.1200dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001358342.1" sequenceAccession="NP_001358342" sequenceVersion="1" change="p.Val402fs">
            <Expression>NP_001358342.1:p.Val402fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001371414.1" sequenceAccession="NM_001371414" sequenceVersion="1" change="c.1200dup">
            <Expression>NM_001371414.1:c.1200dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001358343.1" sequenceAccession="NP_001358343" sequenceVersion="1" change="p.Val402fs">
            <Expression>NP_001358343.1:p.Val402fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_025243.4" sequenceAccession="NM_025243" sequenceVersion="4" change="c.1212dup" MANESelect="true">
            <Expression>NM_025243.4:c.1212dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_079519.1" sequenceAccession="NP_079519" sequenceVersion="1" change="p.Val406fs">
            <Expression>NP_079519.1:p.Val406fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_025243.4(SLC19A3):c.1212dup (p.Val406fs) AND Biotin-responsive basal ganglia disease" Accession="RCV003613096" Version="1">
        <ClassifiedConditionList TraitSetID="1254">
          <ClassifiedCondition DB="MedGen" ID="C1843807">Biotin-responsive basal ganglia disease</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-02-10" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-02-10" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2024-02-20" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">15871139</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23742248</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24166474</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27749535</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="1254" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="585" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Biotin-thiamine-responsive basal ganglia disease</ElementValue>
                <XRef ID="Basal+Ganglia+Disease%2C+Biotin-Responsive/756" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Biotin-responsive basal ganglia disease</ElementValue>
                <XRef ID="MONDO:0011841" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Thiamine metabolism dysfunction syndrome 2 (biotin- or thiamine-responsive encephalopathy type 2)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Thiamine metabolism dysfunction syndrome type 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Thiamine Transporter-2 Deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">thiamine-responsive encephalopathy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- AND THIAMINE-RESPONSIVE TYPE)</ElementValue>
                <XRef Type="MIM" ID="607483" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">BBGD</ElementValue>
                <XRef Type="MIM" ID="607483" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">THMD2</ElementValue>
                <XRef Type="MIM" ID="607483" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">BBTGD</ElementValue>
                <XRef Type="MIM" ID="607483" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Biotin-thiamine-responsive basal ganglia disease (BTBGD) may present in childhood, early infancy, or adulthood. The classic presentation of BTBGD occurs in childhood (age 3-10 years) and is characterized by recurrent subacute encephalopathy manifest as confusion, seizures, ataxia, dystonia, supranuclear facial palsy, external ophthalmoplegia, and/or dysphagia which, if left untreated, can eventually lead to coma and even death. Dystonia and cogwheel rigidity are nearly always present; hyperreflexia, ankle clonus, and Babinski responses are common. Hemiparesis or quadriparesis may be seen. Episodes are often triggered by febrile illness or mild trauma or stress. Simple partial or generalized seizures are easily controlled with anti-seizure medication. An early-infantile Leigh-like syndrome / atypical infantile spasms presentation occurs in the first three months of life with poor feeding, vomiting, acute encephalopathy, and severe lactic acidosis. An adult-onset Wernicke-like encephalopathy presentation is characterized by acute onset of status epilepticus, ataxia, nystagmus, diplopia, and ophthalmoplegia in the second decade of life. Prompt administration of biotin and thiamine early in the disease course results in partial or complete improvement within days in the childhood and adult presentations, but most with the infantile presentation have had poor outcome even after supplementation with biotin and thiamine.</Attribute>
                <XRef ID="NBK169615" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10237" />
                <XRef ID="10237" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24260777</ID>
                <ID Source="BookShelf">NBK169615</ID>
              </Citation>
              <XRef ID="199348" DB="Orphanet" />
              <XRef ID="65284" DB="Orphanet" />
              <XRef ID="C1843807" DB="MedGen" />
              <XRef ID="MONDO:0011841" DB="MONDO" />
              <XRef Type="MIM" ID="607483" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="8222216" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2024-02-20">
        <ClinVarSubmissionID localKey="18345711|MedGen:C1843807" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004436830" DateUpdated="2024-02-20" DateCreated="2024-02-20" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-02-10">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">15871139</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23742248</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24166474</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27749535</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Val406Glyfs*72) in the SLC19A3 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 91 amino acid(s) of the SLC19A3 protein. This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with SLC19A3-related conditions. This variant disrupts a region of the SLC19A3 protein in which other variant(s) (p.Thr422Ala) have been determined to be pathogenic (PMID: 15871139, 23742248, 24166474, 27749535). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC19A3" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000002.11:g.228552983_228552984insG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1843807" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14200279</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="8222216" TraitType="Disease" MappingType="XRef" MappingValue="C1843807" MappingRef="MedGen">
        <MedGen CUI="C1843807" Name="Biotin-responsive basal ganglia disease" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

